Cross walk - 2023 form changes

FoodNet

- 1. FoodNet Active Surveillance Data Elements List Attachment #3
 Refer to Attachment #3 Changes are highlighted in Yellow
- 2. FoodNet Hemolytic Uremic Syndrome Data Elements List Attachment #4 Refer to Attachment #4 Changes are highlighted in Yellow
- 3. Diagnostic Laboratory Practices and Volume Elements List Attachment #5 Refer to Attachment #5 Changes are highlighted in Yellow

FluSurv-Net

1) FluSurv-NET Influenza Surveillance Project Case Report Form- Attachment #6

Question on 2021-22 Form	Question on 2022-23 Form	
C9. Race: White Black or African American Asian/Pacific Islander American Indian or Alaska Native Multiracial Not specified	C8. Race (select all that apply): White Black or African American Asian Native Hawaiian or Other Pacific Islander American Indian or Alaska Native Multiracial, not otherwise specified Not specified	
C2. Admission Type - Hospitalization - Observation only	Deleted question C2 regarding Admission Type	
Hlj. Pregnant	C12. Pregnant (15-49 years of age only):	
- Yes	• Yes	
- No/Unknown	No/Unknown	
	Not applicable (Male)	
This question was not present	 H 10. Mental Health Conditions [] Yes [] No/Unknown Anxiety disorder Bipolar disorder Depression Schizophrenia spectrum disorder 	
I1. Were any culture tests performed within 7	I1 Were any culture tests performed within 3 days prior	
days of admission? (for patients that died in	to or 3 days following admission	
the hospital, include culture tests performed	- Yes	
either 1) within 7 days of admission, 2) within	- No	
3 days prior to death, or 3) within 24 hours	- Unknown	
after death?		
- Yes		
- No		

Question on 2021-22 Form	Question on 2022-23 Form	
- Unknown		
J1. Was the patient tested for any viral	J1. Was the patient tested for any viral pathogen within	
pathogen within 14 days prior to or within 7	14 days prior to or within <= 3 days after admission?	
days of admission?	- Yes	
- Yes	- No	
- No	Unknown	
- Unknown		
I2. If yes, was there a positive culture for	I2c. Result of culture	
aspergillus, mucormycosis, or a bacterial	- Positive	
pathogen?	- Negative	
- Yes	- Unknown	
- No		
- Unknown		
I2a. If yes, specify pathogen	I2d. If positive, what pathogen was identified?	
- Aspergillus (fungus)	- Bacteria, specify	
- Mucormycosis (fungus)	- Aspergillus (fungus)	
- Bacteria, specify	- Mucormycosis (fungus)	
K2C. Treatment End Date	This question was deleted	
- Date or Unknown		
M1. Did the patient have any of the following	M1. Did the patient have any of the following new	
new diagnoses at discharge (select all that	diagnoses at discharge (select all that apply)	
apply)		
	 All diagnoses that were previously collected are 	
	also collected this season	
	 Mucormycosis was added as a new diagnosis 	

2) FluSurv-NET/RSV Laboratory Survey- Attachment #7

Question on 2021-22 form	Question on 2022-23 form 4a. Select the kit names for the rapid influenza diagnostic tests performed or planned to be used at the laboratory (check all that apply)	
4a. Select the kit names for the rapid influenza diagnostic tests performed or planned to be used at the laboratory (check all that apply)		
Acucy Influenza A&B Test (Sekisui Diagnostics, LLC)	Acucy Influenza A&B Test (Sekisui Diagnostics, LLC)	
☐ BD Veritor™ System for Rapid Detection of Flu A+B (CLIA-waived), (Becton Dickinson & Co.)	□ BD Veritor™ System for Rapid Detection of Flu A+B (CLIA-wai (Becton Dickinson & Co.)	
 □ BD Veritor™ System for Rapid Detection of Flu A+B, (Becton Dickinson & C □ Binax NOW® Influenza A&B Card 2 (Abbott) 	BD Veritor™ System for Rapid Detection of Flu A+B (Moderate (Becton Dickinson & Co.)	
☐ BioSign® Flu A+B or OraSure QuickFlu Rapid A+B Test or Polymedco Poly st Flu A&B Test or LifeSign LLC Status Flu A&B (Princeton BioMedtech Corp.)	BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flue Dickinson & Co.) Binax NOW® Influenza A&B Card 2 (Abbott)	

CareStart Flu A&B Plus, (Access Bio, Inc.) OSOM Ultra Plus Flu A&B Test (Sekisui Diagnostics, LLC) QuickVue® Influenza A+B Test (Quidel Corp.) Sofia® Analyzer and Influenza A+B FIA (CLIA-waived) (Quidel Corp.) XPECT™ Influenza A/B (Remel Inc./Thermo Fisher Scientific) Other, specify:	BioSign® Flu A+B or OraSure QuickFlu Rapid A+B Test or Poly Poly stat Flu A&B Test or LifeSign LLC Status Flu A&B (Prince BioMedtech Corp.) OSOM Ultra Plus Flu A&B Test (Sekisui Diagnostics, LLC) QuickVue® Influenza A+B Test (Quidel Corp.) SARS-CoV-2 & Flu A/B Rapid Antigen Test (Roche) Sofia® Analyzer and Influenza A+B FlA (CLIA-waived) (Quidel Corp.) Sofia® Analyzer and Influenza A+B FlA (Quidel Corp.) XPECT™ Influenza A/B (Remel Inc./Thermo Fisher Scientific) Other, specify:
5A. Select Kit names for all molecular assays performed or	5A. Select Kit names for all molecular assays
planned to be used at the laboratory (check all that apply)	performed or planned to be used at the laboratory
☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott)	(check all that apply)
☐ Accula Flu A/Flu B (Mesa Biotech, Inc.) [†]	☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott) [†]
ARIES® Flu A/B & RSV Assay, (Luminex)	☐ Accula Flu A/Flu B (Mesa Biotech, Inc.) [†]
☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)*	Alinity M Resp-4 Plex Assay (Abbott) [‡]
☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡	Aptima SARS-CoV-2/Flu/A/B‡
☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	☐ ARIES® Flu A/B & RSV Assay, (Luminex)
(Influenza A Subtyping Kit), (CDC Influenza Division)	BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)*
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	BioFire Pneumonia Panel (Biomerieux)
(Influenza A/B Typing Kit), (CDC Influenza Division)	BioFire Pneumonia plus Panel (Biomerieux)
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	☐ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡
(Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* [‡]
(Influenza B Lineage Genotyping Kit)	
☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡	CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Pan
Cepheid Xpert Flu Assay, (Cepheid)	(Influenza A Subtyping Kit), (CDC Influenza Division)
Cepheid Xpert Flu/RSV XC Assay, (Cepheid)	□ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR P Probe Set, (CDC Influenza Division)
Cepheid Xpert Express Flu Assay, (Cepheid)	CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Pan
☐ Cepheid Xpert Express Flu/RSV Assay, (Cepheid) ☐ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) [‡]	(Influenza A/B Typing Kit), (CDC Influenza Division)
Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV (CLIA-waived), (Cepheid)	CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) [‡]
☐ Cobas Liat Influenza A/B, (Roche Diagnostics) [†]	☐ Cobas Liat Influenza A/B, (Roche Diagnostics) [†]
Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)†	Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)
☐ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)‡ ☐ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnosti	☐ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)‡
□ ePlex Respiratory Pathogen Panel (GenMark Diagnostics)*†‡	☐ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche
erlex respiratory Pathogen Panel 2, (Genmark Diagnostics)*	☐ ePlex Respiratory Pathogen Panel (GenMark Diagnostics)*†‡
eSensor® Respiratory Viral Panel (RVP), (GenMark Diagnostics)*	☐ ePlex Respiratory Pathogen Panel 2, (Genmark Diagnostics)*‡
FilmArray® Pneumonia Panel plus, (BioFire Diagnostics)	eSensor® Respiratory Viral Panel (RVP), (GenMark Diagnostics)
1	

FilmArray® Pneumonia Panel, (BioFire Diagnostics)	☐ FluChip-8G Influenza A+B Assay, (InDevR)*
☐ FilmArray® Respiratory Panel, (BioFire Diagnostics, LLC)*	☐ Idylla Respiratory IFV-RSV Panel, (Biocartis)*
☐ FilmArray® Respiratory Panel 2 (BioFire Diagnostics, LLC)*	☐ IMDx Flu A/B and RSV for Abbott <i>m</i> 2000, (IMDx)
☐ FilmArray® Respiratory Panel, EZ (BioFire Diagnostics, LLC)*	Lyra Influenza A+B Assay, (Quidel)
☐ FluChip-8G Influenza A+B Assay, (InDevR)*	
☐ Idylla Respiratory IFV-RSV Panel, (Biocartis)*	Nx-TAG Respiratory Pathogen Panel, (Luminex Molecular Diagno
☐ IMDx Flu A/B and RSV for Abbott m2000, (IMDx)	☐ Panther Fusion® Flu A/B RSV, (Assay Hologic)
Lyra Influenza A+B Assay, (Quidel)	☐ Prodesse PROFLU™, (GenProbe/Hologic)
☐ Nx-TAG Respiratory Pathogen Panel, (Luminex Molecular Diagnostics Inc)*	☐ Prodesse ProFAST™, (GenProbe/Hologic)*
☐ Panther Fusion® Flu A/B RSV, (Assay Hologic)	☐ QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN)*‡
☐ Prodesse PROFLU™, (GenProbe/Hologic)	Quest Diagnostics RC COVID-19 +Flu RT-PCR, (Quest Diagnos
☐ Prodesse ProFAST™, (GenProbe/Hologic)*	☐ Silaris Infuenza A & Btg, (Sekisui Diagnostic) [†]
☐ QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN)* [‡]	Sofia 2 Flu + SARS Antigen FIA, (Quidel) ^{†‡}
Quest Diagnostics RC COVID-19 +Flu RT-PCR, (Quest Diagnostics)‡	Solana Influenza A+B Assay, (Quidel)
Silaris Infuenza A & Btg, (Sekisui Diagnostic)†	☐ Simplexa™ Flu A/B & RSV, (Focus Diagnostics, 3M)
Sofia 2 Flu + SARS Antigen FIA, (Quidel) ††	Simplexa™ Flu A/B & RSV Direct, (Focus Diagnostics, 3M)
☐ Solana Influenza A+B Assay, (Quidel)	☐ Simplexa™ Influenza A H1N1 (2009), (Focus Diagnostics, 3M)
☐ Simplexa™ Flu A/B & RSV, (Focus Diagnostics, 3M)	☐ Simplexa™ Flu A/B & RSV Gen II (Diasorin)*
☐ Simplexa™ Flu A/B & RSV Direct, (Focus Diagnostics, 3M)	Verigene® Respiratory Pathogen Nucleic Acid Test (RP Flex), (Li
☐ Simplexa™ Influenza A H1N1 (2009), (Focus Diagnostics, 3M)	Xpert Xpress COV-2/Flu/RSV plus ^{†‡}
Simplexa™ Flu A/B & RSV Gen II (Diasorin)*	☐ Xpert Xpress Flu Assay, (Cepheid) [†]
☐ Verigene® Respiratory Virus Nucleic Acid Test, (Nanosphere, Inc)	Xpert Xpress Flu/RSV Assay, (Cepheid) †
☐ Verigene® Respiratory Virus Plus Nucleic Acid Test (RV+), (Luminex)	☐ Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) ^{†‡}
☐ Verigene® Respiratory Pathogen Nucleic Acid Test (RP Flex), (Luminex)*	x-TAG® Respiratory Viral Panel Fast (RVP FAST),
x-TAG® Respiratory Viral Panel Fast (RVP FAST),	(Luminex Molecular Diagnostics Inc)*
(Luminex Molecular Diagnostics Inc)* ☐ In-house developed PCR assay	☐ In-house developed PCR assay
Other, specify:	Other, specify:
†= Rapid Molecular *= can detect subtype	†= Rapid Molecular *= can detect subtype
- Hapla Molecular — carracted subtype +-Maliplex for influenzación le cov z	- napid Molecular - can detect subtype +-Multiplex for influenza on
5B If more than one kit is selected above, please select the	5B If more than one kit is selected above, please
one kit name that is (or will be) used most frequently for	select the one kit name that is (or will be) used
molecular assay at the laboratory during the current	
molecular assay at the laboratory during the current	most frequently for molecular assay at the
influenza season:	most frequently for molecular assay at the laboratory during the current influenza season:
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott)	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)†
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.) [†]	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)†
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex)	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)*	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)*
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division)	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)*
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ BioFire Pneumonia Panel (Biomerieux)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division)	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ BioFire Pneumonia Panel (Biomerieux) ☐ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)* ☐
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division)	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ BioFire Pneumonia Panel (Biomerieux) ☐ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)* □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioFire Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay	most frequently for molecular assay at the laboratory during the current influenza season: ☐ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ Alinity M Resp-4 Plex Assay (Abbott)‡ ☐ Aptima SARS-CoV-2/Flu/A/B‡ ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ BioFire Pneumonia Panel (Biomerieux) ☐ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)* ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Pneumonia plus Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ ☐ Cepheid Xpert Flu Assay, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Pneumonia plus Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR Probe Set, (CDC Influenza Division)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ ☐ Cepheid Xpert Flu Assay, (Cepheid) ☐ Cepheid Xpert Flu/RSV XC Assay, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Pneumonia plus Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*† □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*† □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ ☐ Cepheid Xpert Flu Assay, (Cepheid) ☐ Cepheid Xpert Flu/RSV XC Assay, (Cepheid) ☐ Cepheid Xpert Express Flu Assay, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Pneumonia plus Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division)
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ ☐ Cepheid Xpert Flu Assay, (Cepheid) ☐ Cepheid Xpert Flu/RSV XC Assay, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)* □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay
influenza season: □ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ARIES® Flu A/B & RSV Assay, (Luminex) □BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ □BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) □Cepheid Xpert Flu Assay, (Cepheid) □Cepheid Xpert Flu/RSV XC Assay, (Cepheid) □Cepheid Xpert Express Flu Assay, (Cepheid) □Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*† □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*† □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division)‡
influenza season: ☐ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) ☐ Accula Flu A/Flu B (Mesa Biotech, Inc.)† ☐ ARIES® Flu A/B & RSV Assay, (Luminex) ☐ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ ☐ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) ☐ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) ☐ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ ☐ Cepheid Xpert Flu Assay, (Cepheid) ☐ Cepheid Xpert Express Flu Assay, (Cepheid) ☐ Cepheid Xpert Express Flu Assay, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*† □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*† □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division)‡ □ Cobas Liat Influenza A/B, (Roche Diagnostics)†
influenza season: □ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ARIES® Flu A/B & RSV Assay, (Luminex) □BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*† □BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) † □Cepheid Xpert Flu Assay, (Cepheid) □Cepheid Xpert Flu/RSV XC Assay, (Cepheid) □Cepheid Xpert Express Flu Assay, (Cepheid) □Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division)‡ □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)† □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)†
influenza season: □ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ARIES® Flu A/B & RSV Assay, (Luminex) □BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*† □BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) † □Cepheid Xpert Flu Assay, (Cepheid) □Cepheid Xpert Flu Assay, (Cepheid) □Cepheid Xpert Express Flu Assay, (Cepheid) □Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □Cepheid Xpert Express SARS-CoV-2/Flu/RSV, (Cepheid) □Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV (CLIA-waived), (Cepheid) □Cepheid Xpert XpressSARS-CoV-2/Flu/RSV (CLIA-waived), (Cepheid) □Cobas Liat Influenza A/B, (Roche Diagnostics)†	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division)‡ □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics);
influenza season: □ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ □ BioCode Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ □ Cepheid Xpert Flu Assay, (Cepheid) □ Cepheid Xpert Flu/RSV XC Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cobas Liat Influenza A/B, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)†	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division)² □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche
influenza season: □ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ □ BioCode Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ □ Cepheid Xpert Flu Assay, (Cepheid) □ Cepheid Xpert Flu/RSV XC Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostic	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) □ CDC Influenza A/B, (Roche Diagnostics)† □ Cobas Liat Influenza A/B, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Plex Respiratory Pathogen Panel (GenMark Diagnostics)*†
influenza season: □ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ □ Cepheid Xpert Flu Assay, (Cepheid) □ Cepheid Xpert Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cobas Liat Influenza A/B, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostic) □ ePlex Respiratory Pathogen Panel (GenMark Diagnostics)* □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostic) □ ePlex Respiratory Pathogen Panel (GenMark Diagnostics)* □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostics) □ ePlex Respiratory Pathogen Panel (GenMark Diagnostics)* □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostics)	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)* □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Subtyping Kit), (CDC Influenza Division) □ CDC Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza A/B, (Roche Diagnostics)† □ Cobas Liat Influenza A/B, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche ePlex Respiratory Pathogen Panel (GenMark Diagnostics)*† □ ePlex Respiratory Pathogen Panel 2, (Genmark Diagnostics)*†
influenza season: □ ID NOW™ Influenza A & B 2 (CLIA waived), (Abbott) □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ)*‡ □ BioCode Respiratory Panel 2.1 (RP2.1) (BioFire Diagnostics, LLC)*‡ □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A Subtyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (Influenza B Lineage Genotyping Kit) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) ‡ □ Cepheid Xpert Flu Assay, (Cepheid) □ Cepheid Xpert Flu/RSV XC Assay, (Cepheid) □ Cepheid Xpert Express Flu Assay, (Cepheid) □ Cepheid Xpert Express Flu/RSV Assay, (Cepheid) □ Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid) □ Cobas Liat Influenza A/B & RSV, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Diagnostic	most frequently for molecular assay at the laboratory during the current influenza season: □ ID Now™ Influenza A&B (CLIA Waived), (Abbott)† □ Accula Flu A/Flu B (Mesa Biotech, Inc.)† □ Alinity M Resp-4 Plex Assay (Abbott)‡ □ Aptima SARS-CoV-2/Flu/A/B‡ □ ARIES® Flu A/B & RSV Assay, (Luminex) □ BioCode Respiratory Pathogen Panel, (Applied BioCode Inc)* □ BioFire Pneumonia Panel (Biomerieux) □ BioFire Respiratory Panel 2.1 (RP2.1) (Biomerieux)*‡ □ BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ) (Biomerieux)*‡ □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza B Lineage Genotyping Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/H5 (Asian Lineage) Virus Real-Time RT-PCR F Probe Set, (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Par (Influenza A/B Typing Kit), (CDC Influenza Division) □ CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay (CDC Influenza Division) □ CDC Influenza A/B, (Roche Diagnostics)† □ Cobas Liat Influenza A/B, (Roche Diagnostics)† □ Cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test, (Roche Plex Respiratory Pathogen Panel (GenMark Diagnostics)*†

2022 influenza season, approximately what percent of the time are each of these test types used to test for flu overall	2021-2022 influenza season, approximately what percent of the time are each of these test types used to test for flu overall
7. Based on tests that were performed during the 2021-	☐ Not applicable (no pediatric testing)7. Based on tests that were performed during the
Standard Molecular assay (e.g. RT-PCR, NAAT) – multiplex/respiratory viral panel (RVP) Not applicable (no adult testing)	Standard Molecular assay (e.g. RT-PCR, NAAT) – singleplex (influence) Standard Molecular assay (e.g. RT-PCR, NAAT) – dualplex/multi- respiratory viral panel (RVP)
 □ Rapid influenza antigen diagnostic test (rapid test, RIDT) □ Rapid Molecular assay (e.g. RT-PCR, NAAT) – singleplex or duplex† □ Standard Molecular assay (e.g. RT-PCR, NAAT) – singleplex (influenza only) 	 □ Rapid influenza antigen diagnostic test (rapid test, RIDT) □ Rapid Molecular assay (e.g. RT-PCR, NAAT) - singleplex (influe □ Rapid Molecular assay (e.g. RT-PCR, NAAT) - dualplex/multiple
6B. Which influenza test method does the laboratory perform most frequently for adult patients (aged >= 18 years)?	6B. Which influenza test method does the laboratory perform most frequently for adult patients (aged >= 18 years)?
That applicable (no pediatile testing)	☐ Not applicable (no pediatric testing)
Standard Molecular assay (e.g. RT-PCR, NAAT) – multiplex/respiratory viral panel (RVP) Not applicable (no pediatric testing)	☐ Standard Molecular assay (e.g. RT-PCR, NAAT) – singleplex (influ☐ Standard Molecular assay (e.g. RT-PCR, NAAT) – dualplex/mult respiratory viral panel (RVP)
Standard Molecular assay (e.g. RT-PCR, NAAT) – singleplex (influenza on	☐ Rapid Molecular assay (e.g. RT-PCR, NAAT) - singleplex (influe
 □ Rapid influenza antigen diagnostic test (rapid test, RIDT) □ Rapid Molecular assay (e.g. RT-PCR, NAAT) – singleplex or dualplex[†] 	Rapid influenza antigen diagnostic test (rapid test, RIDT)
perform most frequently for pediatric patients (0-17 years)?	laboratory perform most frequently for pediatric patients (0-17 years)?
6A. Which influenza test method does the laboratory	6A. Which influenza test method does the
Other, specify: †= Rapid Molecular *= can detect subtype	†= Rapid Molecular *= can detect subtype ‡=Multiplex for influenza/S
☐ In-house developed PCR assay	☐ In-house developed PCR assay ☐ Other, specify:
x-TAG [®] Respiratory Viral Panel Fast (RVP FAST), (Luminex Molecular Diagnostics Inc)*	(Luminex Molecular Diagnostics Inc)*
☐ Verigene® Respiratory Pathogen Nucleic Acid Test (RP Flex), (Luminex)*	x-TAG® Respiratory Viral Panel Fast (RVP FAST),
☐ Verigene® Respiratory Virus Nucleic Acid Test, (Nanosphere, Inc) ☐ Verigene® Respiratory Virus Plus Nucleic Acid Test (RV+), (Luminex)	□ Xpert Xpress Flu/RSV Assay, (Cepheid) † □ Xpert Xpress SARS-CoV-2/Flu/RSV, (Cepheid)†‡
☐ Simplexa [™] Flu A/B & RSV Gen II (Diasorin)	Xpert Xpress Flu Assay, (Cepheid)†
☐ Simplexa™ Influenza A H1N1 (2009), (Focus Diagnostics, 3M)*	Xpert Xpress COV-2/Flu/RSV plus ^{†‡}
☐ Simplexa™ Flu A/B & RSV Direct, (Focus Diagnostics, 3M)	☐ Verigene® Respiratory Pathogen Nucleic Acid Test (RP Flex), (
∐ Solana Influenza A+B Assay, (Quidel) □ Simplexa™ Flu A/B & RSV, (Focus Diagnostics, 3M)	☐ Simplexa "Initideriza A HTMT (2009), (Focus Diagnostics, SW)
Sofia 2 Flu + SARS Antigen FIA, (Quidel) ^{†‡}	 Simplexa™ Flu A/B & RSV Direct, (Focus Diagnostics, 3M) Simplexa™ Influenza A H1N1 (2009), (Focus Diagnostics, 3M)
☐ Silaris Infuenza A & Btg, (Sekisui Diagnostic) [†]	Simplexa™ Flu A/B & RSV, (Focus Diagnostics, 3M)
☐ QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN)*‡ ☐ Quest Diagnostics RC COVID-19 +Flu RT-PCR, (Quest Diagnostics)‡	Solana Influenza A+B Assay, (Quidel)
☐ Prodesse ProFAST™, (GenProbe/Hologic)*	☐ Sofia 2 Flu + SARS Antigen FIA, (Quidel) †‡
☐ Prodesse PROFLU™, (GenProbe/Hologic)	Silaris Infuenza A & Btg, (Sekisui Diagnostic)†
Panther Fusion® Flu A/B RSV, (Assay Hologic)	Quest Diagnostics RC COVID-19 +Flu RT-PCR, (Quest Diagno
☐ Lyra Influenza A+B Assay, (Quidel) ☐ Nx-TAG Respiratory Pathogen Panel, (Luminex Molecular Diagnostics Inc)'	□ Prodesse ProFAST™, (GenProbe/Hologic)* □ QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN)*‡
☐ IMDx Flu A/B and RSV for Abbott m2000, (IMDx) ☐ Lyra Influenza A+B Assay, (Quidel)	☐ Prodesse PROFLU™, (GenProbe/Hologic)
☐ Idylla Respiratory IFV-RSV Panel, (Biocartis)*	Panther Fusion® Flu A/B RSV, (Assay Hologic)
☐ FluChip-8G Influenza A+B Assay, (InDevR)*	☐ Nx-TAG Respiratory Pathogen Panel, (Luminex Molecular Diag
☐ FilmArray® Respiratory Panel 2 (BioFire Diagnostics, LLC)* ☐ FilmArray® Respiratory Panel, EZ (BioFire Diagnostics, LLC)*	☐ Lyra Influenza A+B Assay, (Quidel)
FilmArray® Respiratory Panel, (BioFire Diagnostics, LLC)*	☐ Idylla Respiratory IFV-RSV Panel, (Biocartis)* ☐ IMDx Flu A/B and RSV for Abbott m2000, (IMDx)
FilmArray® Pneumonia Panel, (BioFire Diagnostics)	FluChip-8G Influenza A+B Assay, (InDevR)*

 — % Other test type — % Rapid influenza antigen diagnostic test (rapid test, RIDT) — % Rapid Molecular assay (e.g. RT-PCR, NAAT) – singleplex or d — % Standard Molecular assay (e.g. RT-PCR, NAAT) – singleplex d — % Standard Molecular assay (e.g. RT-PCR, NAAT) – multiplex/rg — % Standard Molecular assay (e.g. RT-PCR, NAAT) – multiplex/rg — — —	 % Other test type % Rapid influenza antigen diagnostic test (rapid test, % Rapid Molecular assay (e.g. RT-PCR, NAAT) - singl % Rapid Molecular assay (e.g. RT-PCR - dualplex/mu % Standard Molecular assay (e.g. RT-PCR, NAAT) - s % Standard Molecular assay (e.g. RT-PCR, NAAT) - d
--	--

HAIC

1. HAIC: Invasive Methicillin-resistant Staphylococcus aureus (MRSA) Infection Case Report Form (Attachment #9)

2022 CRF Question	Changes to the 2023 CRF Question
	2a. Planning region
34a. Did the patient have a positive test(s) for SARS-CoV-2	34a. Did the patient have a positive test(s) for SARS-CoV-
(molecular assay, serology, or other confirmatory test) on	2 (molecular assay, serology, or other confirmatory test)
or in the year before the DISC?	on or in the 90 days before the DISC?
□ Yes □ No □ Unknown	□ Yes □ No □ Unknown
34a.	34a.
IF YES, complete below for MOST RECENT positive test for	Specimen collection dates for positive tests in the 90 days
SARS-CoV-2 on or in the year before the DISC:	before or day of DISC:
Specimen collection date:	First positive test: Unknown
	Most recent positive test: Unknown
Test type:	
□ Antigen	
□ Molecular assay	
□ Serology	
□ Method unknown	
□ Other (specify):	
34a. COVIDNET Case ID:	34a. COVIDNET Case ID:
NNDSS IDs (please provide at least one of the following	
when applicable):	
CDC 2019 NCOV ID:	
Local case ID:	
Local record ID:	
State case identifier:	
Legacy case identifier	

2. HAIC: Invasive Methicillin-sensitive Staphylococcus aureus (MSSA) Infection Case Report Form (Attachment #10)

2022 CRF Question	Changes to the 2023 CRF Question		
	2a. Planning Region		
34a. Did the patient have a positive test(s) for SARS-CoV-2	34a. Did the patient have a positive test(s) for SARS-CoV-		
(molecular assay, serology, or other confirmatory test) on	2 (molecular assay, serology, or other confirmatory test)		
or in the year before the DISC?	on or in the 90 days before the DISC?		
□ Yes □ No □ Unknown	□ Yes □ No □ Unknown		
34a.	34a.		
IF YES, complete below for MOST RECENT positive test for	Specimen collection dates for positive tests in the 90 days		
SARS-CoV-2 on or in the year before the DISC:	before or day of DISC:		
Specimen collection date:	First positive test: Unknown		
🗆 Unknown	Most recent positive test: Unknown		
Test type:			
□ Antigen			
□ Molecular assay			
□ Serology			
□ Method unknown			
□ Other (specify):			
34a. COVIDNET Case ID:	34a. COVIDNET Case ID:		
NNDSS IDs (please provide at least one of the following			
when applicable):			
CDC 2019 NCOV ID:			
Local case ID:			
Local record ID:			
State case identifier:			
Legacy case identifier:			

3. HAIC: Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales / Invasive Escherichia coli (iEC) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Case Report Form (CRF) (Attachment #11)

Question on origina	l 2022 form	Question on 2023 form		Description of change
SARS-CoV-2 (molecu	have a positive test(s) for lar assay, serology, or other the year before or day of	24a. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, antigen, or other viral test, excluding serology) in the 90 days before or day of the DISC? • Yes • No • Unknown		i. Updated the text for the question
	e the table below for the SARS-CoV-2 test in the year DISC:	24b. Specimen collection dates		i. Updated the text for the question ii. Removed the test type iii. Added specimen
Specimen collection date// □ Unknown	Test type □ Molecular assay □ Antigen □ Serology □ Unknown □ Other (specify):	First positive test: Most recent positive test:	// or □ Date unknow // or □ Date unknow	collection date for first and most recent positive test

4. HAIC: Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Case Report Form (CRF) (Attachment #12)

Question on original 2022 form	Question on 2023 form	Description of	
		change	
2022 Carbapenem Resistant	2023 Carbapenem Resistant	I. Updated the year to	
Enterobacteriaceae (CRE)/ Carbapenem	Enterobacterales (CRE)/	2023	
Resistant A. baumannii	Carbapenem Resistant A.	II. Updated	
(CRAB) Multi-site Gram-Negative Surveillance	baumannii	Enterobacteriaceae	
Initiative (MuGSI)	(CRAB) Multi-site Gram-Negative	to Enterobacterales	
Healthcare-Associated Infections Community	Surveillance Initiative (MuGSI)		
Interface (HAIC) Case Report	Healthcare-Associated Infections		
	Community Interface (HAIC) Case		
	Report		
Q2. County	Q2 <mark>a</mark> . County	I. Updated the	
		question number	
Q2b. Planning region		I. Added question	
23b. Risk factors in the 7 days before the DISC:	23b. Risk factors in the 7 days	I. Added a checkbox	
Non-invasive positive pressure ventilation	before the DISC:	for "none"	
(CPAP or BiPAP) at any time in the	Non-invasive positive pressure		
7 calendar days before the DISC	ventilation (CPAP or BiPAP) at any		
Nebulizer treatment at any time in the 7	time in the		

	ul Dice	I	c 11	1
calendar days before		7 calendar days before the DISC		
	on at any time in the 7	• 7 • Nebulizer treatment at any ti		
calendar days before	calendar days before the DISC		days before the	
		DISC		
		 Mechanical vent 	ilation at any	
		time in the 7 caler	ndar days before	
		the DISC		
		• <mark>None</mark>		
24a. Did the patient h	ave a positive test(s) for	24a. Did the patie	nt have a	i. Updated the text
SARS-CoV-2 (molecula	ar assay, serology, or	positive test(s) for	SARS-CoV-2	for the question
other confirmatory te	st) in the year before or	(molecular assay,	<mark>antigen</mark> , or <mark>other</mark>	-
day of the DISC?	•	viral test, excludin	g serology) in	
• Yes		the 90 days before		
• No		DISC?	,	
Unknown		• Yes		
		• No		
		• Unknown		
24b. If yes, complete	the table below for the	24b. Specimen col	lection dates for	i. Updated the text
most recent positive s	SARS-CoV-2 test in the	positive tests in th	e 90 days	for the question
year before or day of	the DISC:	before or day of D	ISC:	ii. Removed the test
,		,		type
				iii. Added specimen
Specimen	Test type	First positive	/ / or	collection date for
collection date	,.	test:	□ Date unknown	first and most recent
//	☐ Molecular assay	Most recent	/ / or	positive test
□ Unknown	_ □ Antigen	positive test:	□ Date unknown	
	□ Serology			
	□ Unknown			
	☐ Other (specify):			
	, , , , , , , , , , , , , , , , , , ,			
	I .	1		

5. HAIC: CDI Case Report and Treatment Form (Attachment #13)

2022 CRF	2023 CRF	Changes
6. County	6a. County	changed question number
[question not on CRF]	6b. Planning region	new question
36. Previous unique CDI episode	38. Previous unique CDI episode	changed question number
37. Any recurrent C. diff+ episodes following this incident C. diff+ episode?	39. Any recurrent C. diff+ episodes following this incident C. diff+ episode?	changed question number
37a. If YES, Date of first recurrent specimen	39a. If YES, Date of first recurrent specimen	changed question number
38. CRF status	40. CRF status	changed question number
39. Initials of SO	41. Initials of SO	changed question number
40. Date of abstraction	42. Date of abstraction	changed question number
41. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, serology, or other confirmatory test) in the year before or day of the DISC?	36. Did the patient have a positive test(s) for SARS-CoV-2 (molecular assay, antigen, or other viral test; excluding serology) in the 90 days before or day of the DISC?	changed question number, changed time period, changed tests under consideration
[question not on CRF]	36a. [Specimen collection dates for positive tests in the 90 days before or day	new question

	of DISC] First positive test:/ / / or □ Date unknown	
41a.1 [If YES, complete below for most recent positive test for SARS CoV-2 in the year before or date of the DISC] - Specimen collection date	36b. [Specimen collection dates for positive tests in the 90 days before or day of DISC] Most recent positive test: / / or □ Date unknown	Reworded, changed time period
41a.2 [If YES, complete below for most recent positive test for SARS CoV-2 in the year before or date of the DISC] - Test type	[question not on CRF]	Removed question
42a. COVID-NET Case ID	37. COVID-NET Case ID	changed question number
42b. NNDSS IDs	[question not on CRF]	Removed question

6. HAIC: CDI Annual Surveillance Officers Survey (Attachment #14)

Existing question	Modified question
2. In 2021, did any laboratories drop out of participation?	2. In 2022, did any laboratories drop out of participation? (changed year to 2022 to reflect change in survey year)
3. In 2021, did you identify any additional laboratories inside or outside of your catchment area which identify <i>C.diff</i> assays from persons who are residents of your catchment area?	3. In 2022, did you identify any additional laboratories inside or outside of your catchment area which identify <i>C.diff</i> assays from persons who are residents of your catchment area? (changed year to 2022 to reflect change in survey year)
10. Did your site complete a physician/outpatient provider survey in 2021?	10. Did your site complete a physician/outpatient provider survey in 2022? (changed year to 2022 to reflect change in survey year)
13. For each facility that treated a case in 2021, please provide the following	13. For each facility that treated a case in 2022, please provide the following (changed year to 2022 to reflect change in survey year)

7. HAIC: Annual Survey of Laboratory Testing Practices for C. difficile Infections (Attachment #15)

2022	2023	Changes
Was this a new laboratory in 2021?	Was this a new laboratory in 2022?	Changed year to 2022 to reflect change
Did this lab participate in surveillance in 2021?	Did this lab participate in surveillance in 2022?	in survey year Changed year to 2022 to reflect change in survey year
How often did you receive line lists from this lab in 2021?	How often did you receive line lists from this lab in 2022?	Changed year to 2022 to reflect change in survey year
How did you receive line lists from this lab in 2021?	How did you receive line lists from this lab in 2022?	Changed year to 2022 to reflect change in survey year
Did you receive specimens from this lab in 2021?	Did you receive specimens from this lab in 2022?	Changed year to 2022 to reflect change in survey year
Was this lab audited in 2021?	Was this lab audited in 2022?	Changed year to 2022 to reflect change in survey year
Types of facilities in your catchment area served by this lab in 2021	Types of facilities in your catchment area served by this lab in 2022	Changed year to 2022 to reflect change in survey year
1. Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2021?	1. Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2022?	Changed year to 2022 to reflect change in survey year
2. What type and order of testing was routinely used by your laboratory in standard testing for C. difficile on December 31, 2021? 1st line of testing: 2nd line of testing: 3rd line of testing:	[question not on survey]	Removed question
2a. Which specimens were used during your 2nd line of testing?	[question not on survey]	Removed question
2b. Which specimens were used during your 3rd line of testing?	[question not on survey]	Removed question
2c. Did your laboratory perform any onsite testing for C. difficile outside of your normal testing algorithm in 2021?	[question not on survey]	Removed question
[question not on survey]	[Question 2a is a table with this heading] Which testing method(s) for Clostridioides	Added table of questions

	difficile (C. difficile) did your laboratory perform in 2022? (Choose all that apply. Include testing methods used for only part of the year or for only a specific subset of specimens, if applicable)	
[question not on survey]	Did your laboratory use this testing method for Clostridioides difficile (C. difficile) in 2022?	Added table of questions
[question not on survey]	[For each testing method selected] Specify when you used this test (e.g. at provider request, for outpatients, for inpatients with a length of stay > 3 days, for every specimen received)	Added table of questions
[question not on survey]	[For each testing method selected] Did you use this testing method in this way for all of 2022?	Added table of questions
[question not on survey]	[For each testing method selected] What date did you change?	Added table of questions
[question not on survey]	[For each testing method selected] What test did you use in this situation before this date?	Added table of questions
3a. Which EIA test kit was used by your laboratory in 2021?	3a. Which EIA test kit was used by your laboratory in 2022?	Changed year to 2022 to reflect change in survey year
3b. Which Nucleic Acid Amplification test was used by your laboratory in 2021?	3b. Which Nucleic Acid Amplification test was used by your laboratory in 2022?	Changed year to 2022 to reflect change in survey year
4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2021, did your laboratory suppress the C. difficile result so that clinicians could not see it?	4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2022, did your laboratory suppress the C. difficile result so that clinicians could not see it?	Changed year to 2022 to reflect change in survey year
4b. If your laboratory used a multiplexed diagnostic in 2022 and the result was suppressed, where does the suppression occur?	4b. If your laboratory used a multiplexed diagnostic in 2022 and the result was suppressed, where does the suppression occur?	Changed year to 2022 to reflect change in survey year
5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2022, did your laboratory suppress the positive NAAT result so that clinicians could not see it?	5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2022, did your laboratory suppress the positive NAAT result so that clinicians could not see it?	Changed year to 2022 to reflect change in survey year
5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2022, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only	5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2022, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only	Changed year to 2022 to reflect change in survey year

result might represent colonization, etc.)?	result might represent colonization, etc.)?	
6. What are the LOINC or internal testing	6. What are the LOINC or internal testing	Changed year
codes associated with the tests your lab	codes associated with the tests your lab	to 2022 to
used in 2022 (e.g. LOINC codes 13957-6,	used in 2022 (e.g. LOINC codes 13957-6,	reflect change
_		
34713-8, or 54067-4)?	34713-8, or 54067-4)?	in survey year
7a. In 2021, did your laboratory experience	[question not on survey]	Removed
any shortages in supplies, reagents, and/or		question
test kits for performing C. difficile testing		
(e.g., NAAT or EIA reagents, swabs)?		
7b. If your laboratory experienced a supply	[question not on survey]	Removed
shortage for C. difficile testing in 2021, how		question
did the shortage affect your laboratory's		
ability to perform C. difficile testing?		
7c. In 2021, did your laboratory experience	[question not on survey]	Removed
a high demand for COVID-19 testing that		question
limited the availability of staff (e.g.,		
reduced staffing or work time) or the use		
of equipment to perform C. difficile		
testing?		
8. Did your lab testing algorithm for C.	[question not on survey]	Removed
difficile change between January 1, 2021	[4444	question
and December 31, 2021?		question
What date did this change occur?/	[question not on survey]	Removed
/	[question not on survey]	question
8a. What was the previous type and order	[question not on survey]	Removed
. , , , , ,	[question not on survey]	
of testing performed by your lab in 2021		question
before it changed its testing algorithm?		
1st line of testing: 2nd line		
of testing: 3rd line of testing:		
9h Which specimens were used during	[guestion not on survey]	Removed
8b. Which specimens were used during	[question not on survey]	
your 2nd line of testing?		question
8c. Which specimens were used during	[question not on survey]	Removed
your 3rd line of testing?		question
9. Did your lab have a policy to reject stool	7. Did your lab have a policy to reject stool	Changed year
specimens for C. difficile testing in 2021?	specimens for C. difficile testing in 2022?	to 2022 to
(Read all options. Check all that apply)	(Read all options. Check all that apply, even	reflect change
☐ Yes, when stools are formed (formed	if it only applies sometimes)	in survey year,
stools are defined as stools that do NOT	☐ Yes, when stools are formed (formed	simplified
take the shape of the container)	stools are defined as stools that do NOT	response
☐ Yes, if there is a stool specimen already	take the shape of the container)	options,
positive within 24 hrs of a new stool	☐ Yes, if there was a positive stool	renumbered
specimen	specimen recently (e.g. within 24 hours,	question
☐ Yes, if there is a stool specimen already	within 7 days)	question
_	-	
positive within 48 hrs of a new stool	☐ Yes, if there was a negative stool	
specimen	specimen recently (e.g. within 24 hours,	
☐ Yes, if there is a stool specimen that	within 7 days)	
tested negative for C. difficile within 48	☐ Yes, will not accept more than one stool	
hours of a new stool specimen	specimen in a 24 hr period	
☐ Yes, will not accept more than one stool	☐ Yes, if patient is on a specific medication	
	(e.g. laxatives)	
specimen in a 24 hr period ☐ No rejection policy	□ No rejection policy	

☐ Other rejection policies Specify other rejection policy:	☐ Other rejection policies Specify other rejection policy:	
9a. Did your rejection policy for stool specimens change between January 1, 2021 and December 31, 2021?	7a. Did your rejection policy for stool specimens change between January 1, 2022 and December 31, 2022?	Changed year to 2022 to reflect change in survey year, renumbered question
10. How many stool samples did you test for C. difficile each month in 2021?	8. How many stool samples did you test for C. difficile each month in 2022?	Changed year to 2022 to reflect change in survey year, renumbered question

8. HAIC: Candidemia Case Report (Attachment #16)

2022 CRF Question	2023 CRF Question
CANDIDEMIA 2022 CASE REPORT FORM (header)	CANDIDEMIA 2023 CASE REPORT FORM (header)
	(changed year)
Version: Short Form 2022, Last Updated: 07/17/2021 (footnotes)	Version: Short Form 2023, Last Updated: 07/29/2022 (footnotes)
	(changed year and date)
23. Incident Specimen Collection Site (check all that apply):	(removed question)
Blood, Central line	
Blood, Peripheral stick	
Blood, not specified	
Other (specify):	
Unknown	
Question 24-25	(changed number by 1)
New Question	25. Did the patient have a culture-independent diagnostic test (CIDT) for Candida, (eg: T2), on the day of or in the 6 days before the DISC?
	1 ☐Yes 0 ☐No 9 ☐Unknown
	25a. If yes, test type:
	25b. Result:
	(appropriate)
20 lufa kina wikh Clasteidiaida difficile	(new question)
30. Infection with <i>Clostridioides difficile</i> on the day of or in the 89 days before or 29 days after the DISC:	(removed question)
1 ☐Yes 0 ☐No 9 ☐Unknown	
30a. If yes, date of first <i>C. diff</i> diagnosis:	
31. Did the patient have any of the following types of infection/colonization related to their Candida infection? (check all that apply):	30. Did the patient have any of the following types of infection related to their Candida infection? (check all that apply):
NoneUnknown	☐None ☐Unknown
Abdominal	Abdominal infection
Hepatobiliary or pancreatic	Hepatobiliary or pancreatic
☐Gl tract	Abscess (specify):
Abscess (specify):	Peritonitis/peritoneal fluid
Peritonitis/peritoneal fluid	Splenic
☐ Splenic	Urinary tract infection

Candiduria	Esophagitis
Esophagitis	Oral/thrush
Oral/thrush	Osteomyelitis
Osteomyelitis	Skin/wound infection
Skin lesions/wounds	Pulmonary infection
Pulmonary	☐Abscess
Abscess	CNS infection (meningitis, brain abscess)
Respiratory specimen with Candida	Eyes
CNS involvement (meningitis, brain abscess)	☐Endophthalmitis
Eyes (endophthalmitis or chorioretinitis)	☐ Chorioretinitis
Endocarditis	Endocarditis
Septic emboli (specify location):	Septic emboli (specify location):
Other (specify):	Other (specify):
	(changed question number, question wording, response options)
Question 32-34	(changed number by 1)
35. Did the patient receive invasive mechanical ventilation in the 30 days	(removed question)
before the DISC, not including the DISC?	
before the DISC, not including the DISC? 1 ☐Yes 0 ☐No 9 ☐Unknown	(changed number by 2)
before the DISC, not including the DISC?	(changed number by 2)
before the DISC, not including the DISC? 1 ☐Yes 0 ☐No 9 ☐Unknown	(changed number by 2) 36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization?
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply):	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply):
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply):
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis)	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized)
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code:	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis)
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code: Specify sub-code:	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis) Specify sub-code:
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified elsewhere) B49 (unspecified mycoses) T80.211 (BSI due to central venous	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified elsewhere)
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown Question 36-37a 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified elsewhere) B49 (unspecified mycoses)	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified
before the DISC, not including the DISC? 1 Yes 0 No 9 Unknown 38. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified elsewhere) B49 (unspecified mycoses) T80.211 (BSI due to central venous	36. Did the patient have any of the following classes or specific ICD-10 codes, including any sub-codes for this hospitalization? (Check all that apply): None Unknown Not applicable (i.e., patient not hospitalized) B37 (candidiasis) Specify sub-code: Specify sub-code: P37.5 (neonatal candidiasis) B48 (other mycoses, not classified elsewhere) B49 (unspecified mycoses)

Other Candida-related code	R65.2 (severe sepsis)
Specify code:	Other <i>Candida</i> -related code
	Specify code:
	(changed question number, added check box option for not applicable)
Question 39-44	(changed number by 2)
45. Other Substances (Check all that apply):	43. Other Substances (Check all that apply):
Mode of Delivery (Check all that apply):	Mode of Delivery (Check all that apply):
☐IDU ☐Skin popping ☐Non-IDU ☐ Unknown	IDU Non-IDU Unknown
□IDU □Skin popping □Non-IDU □	IDU Non-IDU Unknown
Unknown	
□ IDU □Skin popping □Non-IDU □ Unknown	IDU Non-IDU Unknown
IDU Skin popping Non-IDU	□ IDU □ Non-IDU □ Unknown
Unknown	
☐IDU ☐Skin popping ☐Non-IDU ☐ Unknown	□ IDU □ Non-IDU □ Unknown □ IDU □ Non-IDU □ Unknown
☐IDU ☐Skin popping ☐Non-IDU ☐ Unknown	
☐IDU ☐Skin popping ☐Non-IDU ☐ Unknown	(changed question number, removed "Skin popping" as an option)
☐IDU ☐Skin popping ☐Non-IDU ☐ Unknown	
Question 46-50	(changed number by 2)
New Question	49. Did the patient have any ostomies of the gastrointestinal tract including ileostomy, colostomy, etc. in the 30 calendar days before, not including the DISC?
	1 _Yes 0 _No 9 _Unknown
Question 51-53a	(changed number by 2)
53b. Were <u>all</u> CVCs removed or changed on the day of or in the 6 days after the DISC?	52b. Were <u>all</u> CVCs removed or changed in the 2 days before or in the 6 days after the DISC?
1	1
3 CVC removed, but can't find dates 5 Died or discharged before indwelling catheter replaced 9 Unknown	3 CVC removed, but can't find dates 5 Died or discharged before indwelling catheter replaced 9 Unknown
	(changed question number and question wording)

Second S	Question 54-55	(changed number by 1)
CoV-2 test result (molecular assay, serology, or other confirmatory test) from a specimen collected in the 90 days before the DISC or on the DISC? 1 Yes 0 No 9 Unknown Changed question number and question wording) Question 56a-58 (changed number by 1) Steroid(s) given as an outpatient medication associated with candidemia episode prior to Candida DISC, during hospitalization associated with candidemia episode prior to Treatment/management for COVID-19 Question 59 Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC or on the DISC? (changed number by 1) Steroid(s) given as an outpatient medication associated with candidemia episode prior to Candida DISC, during hospitalization associated with candidemia episode (changed question number and response wording, added check box for additional response option) Question 59 Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown Question 61-65 New Question New Question 64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown Seb. Did the patient have a dilated		
1 Yes 0 No 9 Unknown 1 Yes 0 No 9 Unknown (changed question number and question wording) (changed number by 1) 58a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC dandida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes No No No No No No No N	CoV-2 test result (molecular assay, serology, or other confirmatory test) from a specimen collected in the 90 days before the DISC or on the DISC?	CoV-2 test result (molecular assay, antigen, or other confirmatory test, excluding serology) from a specimen collected in the 90 days before the DISC or
9 Unknown O No 9 Unknown (changed question number and question wording) (changed number by 1) Steroid(s) given as an outpatient medication Steroid(s) given as part of treatment/management for COVID-19 Question 59 GO. Did the patient receive any of the following immunomodulatory drugs given as part of treatment/management for COVID-19? Question 59 GO. Did the patient receive any of the following immunomodulatory drugs in the Jod Sarsilumab Baricitinib Unknown Ouestion 60 New Question O No 9 Unknown Steroid(s) given was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication with candidemia episode prior to Candida DISC, during hospitalization associated with candidemia episode candidemia episode Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) (changed number by 1) (changed number by 1) (changed number by 1) (changed number by 2) (changed number by 2) (changed number by 2) Additional response option) (changed number by 2)	l res	1 Yes
9 Unknown 9 Unknown (changed question number and question wording) Question 56a-58 (changed number by 1) 57a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 Question 59 60. Did the patient receive any of the following immunomodulatory drugs in tha 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Changed number by 1) (changed number by 2)	0 No	O.N.s.
Question 56a-58 (changed question number and question wording) (changed number by 1) 58a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 Question 59 (changed question number and response wording, added check box for additional response option) Question 59 (changed question number and response wording, added check box for additional response option) Question 59 (changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) (changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (changed number by 2) (changed number by 1) (changed number by 1) (changed number by 1) (changed number by 1) (changed number by 2) About 1 of the patient receive any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Polysion 61-65 New Question New Question (changed number by 2) 64. Did the patient have an echocardiogram (ECHO), including transhoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown 65. Did the patient have a dilated	9 Unknown	UNO
Question 56a-58 (changed number by 1) 58a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Garicitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Rew Question New Question New Question New Question 65. Did the patient have a dilated		9 Unknown
Question 56a-58 (changed number by 1) 58a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Garicitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Rew Question New Question New Question New Question 65. Did the patient have a dilated		
58a. If yes, what was the reason steroids were administered? (check all that apply) Steroid(s) given as an outpatient medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 Question 59 60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None		
administered? (check all that apply) Steroid(s) given as an outpatient medication steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (changed number by 1) (removed questions) None Tocilizumab Sarilumab Baricitinib Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. Drugstion Goa. If yes were any of the immunomodulatory drugs given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed number by 1) (removed questions) (removed questions)	Question 56a-58	(changed number by 1)
administered? (check all that apply) Steroid(s) given as an outpatient medication steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (changed number by 1) (removed questions) None Tocilizumab Sarilumab Baricitinib Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. Drugstion Goa. If yes were any of the immunomodulatory drugs given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed number by 1) (removed questions) (removed questions)		
administered? (check all that apply) Steroid(s) given as an outpatient medication steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (changed number by 1) (removed questions) None Tocilizumab Sarilumab Baricitinib Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. Drugstion Goa. If yes were any of the immunomodulatory drugs given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as an outpatient medication Steroid(s) given as part of treatment/management for COVID-19 None of the above (changed number by 1) (removed questions) (removed questions)	58a. If yes, what was the reason storoids were	57a. If yes, what was the reason storoids were
medication Steroid(s) given during hospitalization associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 Whose of the above Changed question number and response wording, added check box for additional response option) Question 59 Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) Mone Tocilizumab Sarilumab Baricitinib Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown New Question Goa. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question		
associated with candidemia episode prior to Candida DISC Steroid(s) given as part of treatment/management for COVID-19 Question 59 Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Goa. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown New Question Goa. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question Goa. Did the patient have a dilated		
associated with candidemia episode prior to Candida DISC? Steroid(s) given as part of treatment/management for COVID-19 Question 59 Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown Go. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Go. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) Common Tocilizumab Sarilumab Go. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Go. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question Go. Did the patient have a dilated	Steroid(s) given during hospitalization	
Steroid(s) given as part of treatment/management for COVID-19 None of the above	associated with candidemia episode prior to	
treatment/management for COVID-19 treatment/management for COVID-19 None of the above		
None of the above (changed question number and response wording, added check box for additional response option)		
(changed question number and response wording, added check box for additional response option) Question 59 (changed number by 1) 60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None	treatment/management for COVID 13	
Wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (removed questions)		None of the above
Wording, added check box for additional response option) Question 59 (changed number by 1) (changed number by 1) (removed questions)		
Question 59 (changed number by 1) (changed number by 1) (removed questions)		wording, added check box for additional
60. Did the patient receive any of the following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Question 61-65 (changed number by 2) New Question 64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question New Question 65. Did the patient have a dilated		
following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab Baricitinib Unknown 60a. If yes were any of the immunomodulatory drugs given as part of treatment/management for COVID-19? 1 Yes 0 No 9 Unknown Question 61-65 (changed number by 2) New Question 64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question 65. Did the patient have a dilated	••••	
immunomodulatory drugs given as part of treatment/management for COVID-19? 1	following immunomodulatory drugs in the 30 days before the DISC, not including the DISC? (check all that apply) None Tocilizumab Sarilumab	(removed questions)
New Question 64. Did the patient have an echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question 65. Did the patient have a dilated	immunomodulatory drugs given as part of treatment/management for COVID-19?	
echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the DISC? 1 Yes 0 No 9 Unknown New Question 65. Did the patient have a dilated	Question 61-65	(changed number by 2)
New Question 65. Did the patient have a dilated	New Question	echocardiogram (ECHO), including transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days after the
	New Question	

days after	the DISC?	
1 🗌 Yes	0	9 Unknown

9. HAIC: Laboratory Testing Practices for Candidemia Questionnaire (Attachment #17)

2022 Lab Survey Question	2023 Lab Survey Question
2022 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header)	2023 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header)
	(changed year)
 What kind of laboratory is this facility? (select one) 	1) What kind of laboratory is this? (select one)
Hospital laboratory	Hospital laboratory
Commercial laboratory (Quest, etc.)	Commercial laboratory (Quest, etc.)
Other (specify)	Other (specify)
Unknown	Unknown
	(changed question wording to remove "facility")
2) Does this facility ever receive blood cultures from nursing homes or other long term care facilities?	2) Does this laboratory ever receive blood cultures from nursing homes or other long term care facilities?
Yes	Yes
No	No
Unknown	
	Unknown
	(changed question wording to replace "facility" with "laboratory")
5) What is the approximate volume of any type of fungal cultures performed annually in your laboratory? Specify number: Unknown	5) What is the approximate volume of fungal cultures ordered and performed annually in your laboratory for any specimen type? Specify number: Unknown
	(changed question wording)
6) What is the approximate volume of fungal cultures from blood performed annually in your laboratory? Specify number:	6) What is the approximate volume of fungal blood cultures ordered and performed annually in your laboratory? Specify number:
	(changed question wording)
7) Does this laboratory offer yeast identification	7) Does this laboratory offer yeast identification

either onsite or sent to another laboratory?	(<u>either onsite or sent to another laboratory)</u> ?
Yes	Yes
No ()	No ()
Unknown (is there another laboratory staff	Unknown (is there another laboratory staff
member who can assist with the questionnaire?)	member who can assist with the questionnaire?)
,	,, , , , , , , , , , , , , , , ,
	(added paratheses to question wording, updated skip
	logic in response options)
10) Does this laboratory routinely use Chromagar for	10) Does this laboratory routinely use chromogenic
the identification or differentiation of Candida	agar for the identification or differentiation of
isolates?	Candida isolates?
Yes	Yes
No	No
Unknown	Unknown
	(changed question wording to replace "Chromagar"
	with "chromogenic agar")
11) Species-level identification is performed for	11) Species-level identification is performed for
Candida spp. isolated from which of the	Candida spp. isolated from which of the
following?	following?
n Diagdicaletes	a Blandindston
a. Blood isolates	a. Blood isolates
a. Blood isolates Yes, reflexively	a. Blood isolates Yes, always
Yes, reflexively	Yes, always
Yes, reflexively Yes, with clinician order No	Yes, always Yes, with clinician order No
Yes, reflexively Yes, with clinician order	Yes, always Yes, with clinician order
Yes, reflexively Yes, with clinician order No	Yes, always Yes, with clinician order No
Yes, reflexively Yes, with clinician order No	Yes, always Yes, with clinician order No
Yes, reflexively Yes, with clinician order No Unknown	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the
Yes, reflexively Yes, with clinician order No Unknown	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following?	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following?
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively Yes, with clinician order	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always Yes, with clinician order
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively Yes, with clinician order	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always Yes, with clinician order
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively Yes, with clinician order No	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always Yes, with clinician order No
Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, reflexively Yes, with clinician order No	Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following? b. Other normally sterile body site isolates Yes, always Yes, with clinician order No

11) Species-level identification is performed for Candida spp. isolated from which of the following?	11) Species-level identification is performed for Candida spp. isolated from which of the following?
c. Abdominal isolates Yes, reflexively	c. Abdominal isolates Yes, always
Yes, with clinician order	Yes, with clinician order
No	No
Unknown	Unknown
	(changed first response option wording)
11) Species-level identification is performed for Candida spp. isolated from which of the following?	11) Species-level identification is performed for Candida spp. isolated from which of the following?
d. Respiratory isolates Yes, reflexively	d. Respiratory isolates Yes, always
Yes, with clinician order	Yes, with clinician order
No	No
Unknown	Unknown
	(changed first response option wording)
11) Species-level identification is performed for Candida spp. isolated from which of the following?	(changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the following?
Candida spp. isolated from which of the following? e. Urine isolates	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively	 11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order No	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order No
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order No	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order No
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order No	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order No Unknown
Candida spp. isolated from which of the following? e. Urine isolates Yes, reflexively Yes, with clinician order No Unknown 11) Species-level identification is performed for Candida spp. isolated from which of the	11) Species-level identification is performed for Candida spp. isolated from which of the following? e. Urine isolates Yes, always Yes, with clinician order No Unknown (changed first response option wording) 11) Species-level identification is performed for Candida spp. isolated from which of the

Unknown (changed first response option wording) 13) Does this laboratory employ culture-independent diagnostic tests (CIDT) to identify Candida from blood specimens? Yes (got to q14) No (got to q17) Unknown Unknown (changed first response option wording) 13) Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood specimens? Yes (go to Q14) No (go to Q17) Unknown	
13) Does this laboratory employ culture-independent diagnostic tests (CIDT) to identify Candida from blood specimens? Yes (got to q14) No (got to q17) 13) Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood specimens? Yes (go to Q14) No (go to Q17)	
13) Does this laboratory employ culture-independent diagnostic tests (CIDT) to identify Candida from blood specimens? Yes (got to q14) No (got to q17) 13) Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood specimens? Yes (go to Q14) No (go to Q17)	
diagnostic tests (CIDT) to identify Candida from blood specimens? Yes (got to q14) No (got to q17) diagnostic tests (CIDTs) to identify Candida from blood specimens? Yes (go to Q14) No (go to Q17)	
blood specimens? Yes (got to q14) No (got to q17) blood specimens? Yes (go to Q14) No (go to Q17)	
Yes (got to q14) ☐ Yes (go to Q14) No (got to q17) ☐ No (go to Q17)	
□ No (got to q17) □ No (go to Q17)	
Unknown Unknown	
(shanged guestian wording to undete CIDT	
(changed question wording to update CIDT abbreviation, changed formatting of skip logic in the	
response wording)	
14) Does this laboratory employ the T2Candida Panel 14) Does this laboratory employ the T2Candida Panel	
to identify Candida from blood specimens? to identify Candida from blood specimens?	
Yes (got to 12a) Yes (go to Q14a)	
□ No (go to 13) □ No (go to Q15)	
Unknown Unknown	
(changed formatting of skip logic in the response	
wording)	
14) Does this laboratory employ the T2Candida Panel 14) Does this laboratory employ the T2Candida Panel	
to identify Candida from blood specimens? to identify Candida from blood specimens?	
h. If You does this lab sulture blood if you got a h. If You and you got a positive result on	
b. If Yes, does this lab culture blood if you get a b. If Yes and you get a positive result on positive result on T2Candida Panel? T2Candida Panel, does this lab culture the	
 b. If Yes, does this lab culture blood if you get a positive result on positive result on T2Candida Panel? b. If Yes and you get a positive result on T2Candida Panel, does this lab culture the blood to obtain an isolate? 	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes. always	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, always Yes, with a clinical order Unknown	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown (changed question wording, changed first response option wording)	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, always Yes, with a clinical order Unknown (changed question wording, changed first response	
positive result on T2Candida Panel? T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, reflexively Yes, with a clinical order No Unknown (changed question wording, changed first response option wording) T5) Does this laboratory employ the BioFire T2Candida Panel, does this lab culture the blood to obtain an isolate? Yes, always Yes, with a clinical order No Unknown 15) Does this laboratory employ the BioFire	

Yes (go to 15a)	Yes (go to Q15a)
No (go to 16)	No (go to Q16)
Unknown	Unknown
	(changed formatting of skip logic in the response wording)
15) Does this laboratory employ the BioFire	15) Does this laboratory employ the BioFire
(FilmArray) to identify <i>Candida</i> from blood	(FilmArray) to identify <i>Candida</i> from blood
specimens?	specimens?
specificis.	specificis.
b. If Yes, does this lab reflexively culture blood if you get a positive result on BioFire?	b. If Yes and you get a positive result on BioFire, does this lab culture the blood to obtain an isolate?
Yes, reflexively	
Yes, with a clinical order	Yes, always
No	Yes, with a clinical order
Unknown	No
	Unknown
19) Where is antifungal susceptibility testing (AFST) done? (check the most applicable) On-site, in the laboratory Sent to commercial lab Sent to affiliated hospital lab Sent to other local/regional, non-affiliated reference or public health laboratory Other Unknown	(changed question wording, changed first response option wording) 19) Where is antifungal susceptibility testing (AFST) done? (check the most applicable) On-site, in the laboratory (go to Q20) Sent to commercial lab (If not an on-site laboratory, QUESTIONNAIRE COMPLETE) Sent to affiliated hospital lab Sent to other local/regional, non-affiliated reference or public health laboratory Other Unknown
	(changed skip logic in the response wording)
21) What methods are used for AFST? (check all that apply)	21) What methods are used for AFST, excluding Amphotericin B? (check all that apply)
	Durable received Physics of the Late
Non-commercial broth microdilution	Broth microdilution with laboratory
YeastOne	developed plates
E test	YeastOne (Thermo Scientific™ Sensititre™
Vitek	Gradient diffusion (E test)

Other	Vitek (bioMerieux)
Unknown	Other
	Unknown
	(changed question wording to specify all
	antifungals except Amp B, changed response
	option wording)
a. If you use Vitek for AFST, what Candida species	(removed question)
do you test with it? (check all that apply)	, , , , , , , , , , , , , , , , , , , ,
C. albicans	
C. glabrata	
C. parapsilosis	
Other Candida spp.	
Other curidida spp.	
New question	22) What methods are used for AFST of Amphotericin
	B? (check all that apply)
	Broth microdilution with laboratory
	developed plates
	YeastOne (Thermo Scientific™ Sensititre™
	Gradient diffusion (E test)
	Vitek (bioMerieux)
	Other
	Unknown
	(new question)
22) How does this laboratory meet proficiency testing	23) How does this laboratory meet proficiency testing
requirements for antifungal susceptibility testing,	requirements for antifungal susceptibility testing,
if performed?	if performed?
Commercial provider (specify)	Commercial provider (specify)
Internal alternate assessments (specify)	Internal alternate assessments (specify)
	(changed question number)
23) How are results of AFST reported? (select one)	24) How are results of AFST reported when
Categorical interpretation only (susceptible,	breakpoints are available? (select one)
resistant, etc.)	Categorical interpretation only (susceptible,
MIC only	resistant, etc.)
Bothcategorical interpretation PLUS MIC	MIC only
Unknown	Bothcategorical interpretation PLUS MIC
	Unknown

a. If categorical interpretation only, how do you determine the categorical interpretation? (check all that apply) CLSI M27 S4 CLSI M27 S3 From manufacturer of MIC test Apply epidemiologic breakpoints	(changed question wording to specify when breakpoints are available, changed question number) (removed question)
Other	25) How are results of AFST reported when
	breakpoints aren't available? (select one) MIC only Bothcategorical interpretation PLUS MIC Unknown (new question)
24) For what type of Candida isolates is antifungal susceptibility testing (AFST) performed automatically/reflexively? (check all that apply) Blood isolates Other normally sterile body site isolates Other (specify) No AFST performed automatically (requires order from a clinician) Unknown	26) For what type of Candida isolates is antifungal susceptibility testing (AFST) performed automatically? (check all that apply) Blood isolates Other normally sterile body site isolates Other (specify) No AFST performed automatically (requires order from a clinician) Unknown (changed question wording to remove reflexively,
25) How is AFST performed for the following Candida spp.? a. C. albicans Performed automatically/reflexively (Go to 21ai) Performed with a clinician's order (Go to 21ai) Not performed	changed question number) 27) When is AFST performed for the following Candida spp.? a. C. albicans Performed automatically (Go to 27ai) Performed with a clinician's order (Go to 27ai) Not performed

	(changed question and response wording, updated skip logic, changed question number)
i. Drugs for which AFST is performed automatically/reflexively on C. abicans (check all that apply): Micafungin	i. Drugs for which AFST is performed on C. ablicans (check all that apply): Micafungin Anidulafungin Caspofungin Fluconazole Voriconazole Amphotericin B Other Unknown
	(fixed species misspelling)
25) How is AFST performed for the following Candida spp.? b. C. glabrata Performed automatically/reflexively (Go to 21bi) Performed with a clinician's order (Go to 21bi) Not performed	 27) When is AFST performed for the following Candida spp.? b. C. glabrata Performed automatically (Go to 27bi) Performed with a clinician's order (Go to 27bi) Not performed
	(changed response wording to remove reflexively, updated skip logic)
25) How is AFST performed for the following Candida spp.? c. C. parapsilosis Performed automatically/reflexively (Go to 21ci) Performed with a clinician's order (Go to 21ci) Not performed	 27) When is AFST performed for the following Candida spp.? c. C. parapsilosis Performed automatically (Go to 27ci) Performed with a clinician's order (Go to 27ci) Not performed
	(changed response wording to remove reflexively, updated skip logic)
 25) How is AFST performed for the following Candida spp.? d. Other Candida spp. Performed automatically/reflexively (Go to 	 27) When is AFST performed for the following Candida spp.? d. Other Candida spp. Performed automatically (Go to 27di)

21di)	Performed with a clinician's order (Go to
Performed with a clinician's order (Go to 21di)	27di) Not performed
Not performed	
	(changed response wording to remove reflexively,
	updated skip logic)
New question	28) Is this laboratory tracking susceptibility trends for
	Candida spp. isolates tested in your lab?
	Yes
	No
	Unknown
	(new question)

10. Invasive Staphylococcus aureus Supplemental Surveillance Officer (Attachment #18)

2021 Survey Question	Changes to the 2021 Survey Question
COVID-19 Impact section	COVID-19 Impact section
1. Did COVID-19 response activities delay 2021	1. Did COVID-19 response activities affect or
iSA surveillance work (e.g., unable to meet	delay 2022 iSA surveillance work (e.g.,
iSA deadlines during 2021)?	unable to meet iSA deadlines during 2022)?
yesno	yesno
CDC Responsibilities section	CDC Responsibilities section
1. CDC staff are responsive to	1. CDC staff are responsive to
questions/concerns/emails (e.g., Davina	questions/concerns/emails (e.g., Holly Biggs,
Campbell, Runa Gokhale, Kelly Jackson, Isaac	Davina Campbell, Kelly Jackson, Isaac See,
See, and Shirley Zhang).	and Shirley Zhang).
Strongly agree	Strongly agree
Agree	Agree
Neutral	Neutral
Disagree	Disagree
Strongly disagree	Strongly disagree

11. HAIC: Invasive Staphylococcus aureus Laboratory Survey: Use of Nucleic Acid Amplification Testing (NAAT) (Attachment #19)

2022 Survey Question	2023 Survey Question
2b. If yes when did the change occur?	2a. If yes when did the change occur?
MRSA (i.e., not for MSSA) (Month/year of	MRSA (i.e., not for MSSA) (Month/year of change)
change)/	/
Staphylococcus aureus (i.e., both MRSA and	Staphylococcus aureus (i.e., both MRSA and MSSA)
MSSA) (Month/year of change)	(Month/year of change)
	<u>/</u>
	[Updated question number]
1. Do you routinely set up culture for sterile sites	3. Do you routinely set up culture for sterile sites
(blood, CSF, bone, etc.) on site (in-house) at your	(blood, CSF, bone, etc.) on site (in-house) at your
laboratory?	laboratory?
☐ Yes - GO TO Q2 ☐ No - GO TO Q3	☐ Yes - GO TO Q4 ☐ No - GO TO Q3a
	[Updated question number]
1a. [If no] To which laboratory do you send sterile	3a. [If no] To which laboratory do you send sterile
specimens for culture/identification?	specimens for culture/identification?
	[Updated question number]
	Question 4 asks about methods for identifying S.
	aureus or MRSA from a positive sterile site (blood,
	CSF, bone, etc.) culture.
	[Added section header]
3c. [If using any of the above tests on sterile site	4. If a sterile site culture is positive, is sub-culturing to
specimens] Do you still obtain an isolate for S.	obtain an isolate always performed?
aureus or MRSA? □ Yes □ No - GO to Q4	☐ Yes - GO TO Q4b ☐ No

[question split into two- one for identifying <i>S. aureus</i> via positive sterile site culture and one for identifying <i>S. aureus</i> directly from a sterile site specimen]	5d. Do you still obtain an isolate for <i>S. aureus</i> or MRSA if these tests are used? □ Yes - END SURVEY □ No - END SURVEY [Question split into two]
	4a. [If no] explain/specify reason:
2 In Contract of NADCA worth obtained and find the	[New question]
2. Is <i>S. aureus</i> or MRSA routinely identified via culture-based methods on site (in-house) at your laboratory?	4b. If a sterile site culture is positive, how do you identify it as <i>S. aureus</i> ? This includes identifying both on-site (in-house) or at another lab. (Check all that apply)
☐ Yes - GO TO Q3 ☐ No	□ MALDI-TOF - GO TO 4f
[Updated question to document type of culture-based	☐ Biochemical tests (e.g., catalase, coagulase) – GO TO 4f
methods used rather than yes/no]	☐ Molecular test - GO TO 4c
	☐ Other, specify: GO TO 4f
	☐ Do not identify as S. aureus – GO TO Q5
2a. [If no] To which laboratory do you send cultures for <i>S. aureus</i> identification?	4c. [If molecular test(s) used] Where is molecular testing from a positive sterile site culture completed?
	□ On-site □ Send out, please specify lab GO TO Q4e
	[Updated wording]
3b. Which CIDTs do you use (sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.	4d. Which molecular tests do you use (cultures from sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.
☐ FilmArray® Blood Culture Identification PanelDate started	☐ FilmArray® Blood Culture Identification PanelDate started
☐ Verigene® Gram-Positive Blood Culture TestDate started	☐ Verigene® Gram-Positive Blood Culture TestDate started
☐ Verigene® Staphylococcus Blood Culture TestDate started	☐ Verigene® Staphylococcus Blood Culture TestDate started
☐ Cepheid Xpert® MRSA/SA BCDate	☐ Cepheid Xpert® MRSA/SA BCDate started
started	☐ BD Geneohm® StaphSRDate started
□ BD Geneohm® StaphSRDate started	☐ AdvanDx Staphylococcus QuickFISH blood culture kit
☐ AdvanDx Staphylococcus QuickFISH blood culture kitDate started	Date started
□ AdvanDx S. aureus/CNS PNA FISHDate	☐ AdvanDx S. aureus/CNS PNA FISHDate started
started	☐ Alere BinaxNOW® Staphylococcus aureus testDate
☐ Alere BinaxNOW® <i>Staphylococcus aureus</i> testDate started	started Great Basin Staph ID/R blood culture panelDate
☐ Great Basin Staph ID/R blood culture panelDate started	started
☐ T2Bacteria® PanelDate started	☐ Accelerate PhenoTest™ BC kitDate started
☐ Accelerate PhenoTest™ BC kitDate started	□ iCubate iC-GPC Assay™Date started
	☐ mecA XpressFISH®Date started
☐ iCubate iC-GPC Assay™Date started	☐ Micacom hemoFISH Masterpanel Date started

☐ mecA XpressFISH®Date started	□ ePlex BCID-GP Panel Date started
☐ Micacom hemoFISH Masterpanel Date started	☐ BioFire Blood Culture Identification 2 (BCID2) Panel Date started
□ ePlex BCID-GP Panel Date started	☐ Other, Lab Developed molecular Test (detects MRSA or SA) Date started
☐ Other, Lab Developed Test (detects MRSA or SA) Date started	☐ Other commercial molecular test, SpecifyDate started
☐ Other commercial test, SpecifyDate	
[broke into two questions to separate tests that start with a positive culture from those that start with a	5b. Which tests do you use to detect <i>S. aureus</i> directly from a sterile site source without culture? (sterile site sources only, i.e. blood, CSF, pleural fluid, bone, etc.)? Please check all that apply.
sterile site specimen. One new response option in 4d]	☐ T2Bacteria® PanelDate started
	☐ Karius Test [™] Date started
	☐ Other, Lab Developed Test (detects MRSA or SA) Date started
	☐ Other commercial test, SpecifyDate started
	4e. Are positive molecular tests from sterile site cultures appearing in the <i>S. aureus</i> surveillance laboratory line lists? Yes – GO TO Q5
	□ No - GO TO Q5 □ Unknown - GO TO Q5
	[New question]
3d. [If no] Do you plan to start offering any CIDTs for <i>S. aureus</i> or MRSA within the next year? ☐ Yes ☐ No - END SURVEY [Broke into two questions to separate tests that start	4f. [If not using molecular tests from sterile site cultures on-site] Do you plan to start offering any molecular tests for detection of <i>S. aureus</i> or MRSA from a positive sterile source culture within the next year? No - GO TO Q3
with a positive culture from those that start with a sterile site specimen]	5e. [If no] Do you plan to start offering any tests for detection of <i>S. aureus</i> or MRSA directly from a sterile source within the next year? □ Yes □ No - END SURVEY
3e. When do you plan to start offering CIDTs?	4g. When do you plan to start offering molecular
Month/Year:/	tests? Month/Year:/
[Broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen]	5f. When do you plan to start offering these tests? Month/Year:/
3f. Where do you plan to have CIDT tested?	4h. Where do you plan to have molecular tests
□ On-site □ Send out, please specify lab 	performed? □ On-site □ Send out, please specify lab GO TO Q3
[Broke into two questions to separate tests that start with a positive culture from those that start with a sterile site specimen]	5g. Where do you plan to have these tests performed?

	□ On-site □ Send out, please specify lab END SURVEY
	Question 5 asks about testing performed directly on sterile site specimens (a positive blood culture is not required to perform these tests).
	[Added section header]
3. Do you routinely run any culture independent diagnostic tests (CIDT) on site or at another lab for detection of <i>S. aureus</i> or MRSA either directly	5. Do you routinely run any tests on site (in-house) or at another lab that detect of <i>S. aureus</i> directly from a sterile source (e.g., blood, CSF) without a culture?
from a sterile source (CSF, Blood, etc.) or from a positive blood culture?	☐ Yes ☐ No - GO TO Q5e
☐ Yes ☐ No - GO TO Q3d	[Updated question number. Edited question so it only refers to tests performed directly from a sterile source]
3a. [If yes] Where is CIDT testing completed?	5a. [If yes] Where is this testing completed?
☐ On-site ☐ Send out, please specify lab GO TO Q3c	□ On-site □ Send out, please specify lab GO TO Q5e
	[Updated question number. Edited question so it only refers to tests performed directly from a sterile source]
	5c. Are all positive tests directly from sterile sources appearing in the <i>S. aureus</i> surveillance laboratory line lists?
	□ Yes □ No □ Unknown
	[New question]
4. How does your lab use the CIDT for detection of <i>S. aureus</i> or MRSA? (select one)	
☐ Test concurrently with culture	
$\hfill\square$ Reflex to culture after positive by CIDT panel	
☐ Only run CIDT panel, no additional testing is done ☐ Other, specify [Deleted question]	